Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral L19IL2 in Stage III/IV Melanoma
NCT01253096Phase 2Completed
- Sponsor
- Philogen
- Start
- Apr 2010
- Primary completion
- Sep 2013
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of darleukin in Malignant Melanoma (MM), sponsored by Philogen. Started Apr 2010; status: completed.
02
Drugs
darleukin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT01253096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253096.